tiprankstipranks
Trending News
More News >
Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
:NVLG
Israel Market

Novolog (NVLG) AI Stock Analysis

Compare
1 Followers

Top Page

IL

Novolog

(NVLG)

Rating:73Outperform
Price Target:
162.00
▲(17.90%Upside)
Novolog's strong financial performance is the most significant factor, driven by consistent revenue growth and improved profitability. While the technical analysis shows a mixed picture with potential bearish momentum, the high dividend yield provides a counterbalance in valuation. The overall score reflects a stable financial base with some technical and valuation concerns.

Novolog (NVLG) vs. iShares MSCI Israel ETF (EIS)

Novolog Business Overview & Revenue Model

Company DescriptionNovolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.
How the Company Makes MoneyNovolog generates revenue primarily through the sale of its insulin products and diabetes-related medications. The company's revenue model is based on direct sales to healthcare providers, hospitals, and pharmacies, both domestically and internationally. Novolog also engages in partnerships with healthcare organizations and governments for large-scale distribution agreements. Additionally, the company invests in research and development to continually improve its products, which helps maintain its competitive edge and supports its pricing strategy. Strategic collaborations with other pharmaceutical companies and participation in clinical trials further contribute to its revenue streams.

Novolog Financial Statement Overview

Summary
Novolog demonstrates strong financial health with consistent revenue growth, improved profitability, and solid cash flow generation. The company has shown a turnaround in profitability with a positive net profit margin and improved return on equity. Operational efficiency is also on the rise, and cash flows remain robust, indicating financial stability.
Income Statement
85
Very Positive
Novolog's revenue has shown consistent growth over the years, with a noticeable increase from $1.64 billion to $2.02 billion annually. The company has improved its net profit margin from a negative 2.56% to a positive 1.96%, indicating a turnaround in profitability. Gross profit margin remains stable around 8-9%, while EBIT and EBITDA margins have also improved, reflecting better operational efficiency.
Balance Sheet
78
Positive
The debt-to-equity ratio is moderate at 0.54, suggesting a balanced leverage strategy. Stockholders' equity has decreased slightly, but the equity ratio remains healthy at 12.13%, indicating a strong capital base. Return on Equity has improved significantly, moving from negative to positive, showcasing effective management of equity.
Cash Flow
80
Positive
Operating cash flow is robust, supporting a positive free cash flow trajectory. Free cash flow has decreased slightly compared to the previous year, but the company maintains a strong free cash flow to net income ratio, suggesting effective cash conversion. The cash flow from operations remains strong, underscoring financial stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.09B2.02B1.64B1.51B1.26B1.13B
Gross Profit164.09M180.78M173.76M176.15M148.96M129.29M
EBITDA117.18M149.39M130.14M138.53M115.92M104.05M
Net Income27.37M39.54M-42.00M47.51M42.32M40.07M
Balance Sheet
Total Assets3.12B3.04B2.79B2.43B2.29B2.19B
Cash, Cash Equivalents and Short-Term Investments111.22M247.60M232.94M172.81M238.71M176.44M
Total Debt191.08M198.47M215.18M212.77M166.81M154.24M
Total Liabilities2.73B2.65B2.39B1.97B1.86B1.89B
Stockholders Equity370.37M368.38M371.08M436.00M424.37M294.69M
Cash Flow
Free Cash Flow-3.47M99.78M129.06M63.16M52.75M32.87M
Operating Cash Flow62.91M158.52M200.01M132.65M83.39M58.48M
Investing Cash Flow-58.84M-50.55M-72.60M-124.95M-69.07M-28.61M
Financing Cash Flow-94.14M-94.59M-67.71M-72.96M47.49M-39.85M

Novolog Technical Analysis

Technical Analysis Sentiment
Negative
Last Price137.40
Price Trends
50DMA
144.68
Negative
100DMA
152.78
Negative
200DMA
159.70
Negative
Market Momentum
MACD
-0.92
Negative
RSI
47.57
Neutral
STOCH
40.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 137.4 is below the 20-day moving average (MA) of 140.45, below the 50-day MA of 144.68, and below the 200-day MA of 159.70, indicating a bearish trend. The MACD of -0.92 indicates Negative momentum. The RSI at 47.57 is Neutral, neither overbought nor oversold. The STOCH value of 40.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.

Novolog Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
717.22M25.12
5.58%25.30%
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
$255.17M61.597.41%
ILILX
700.93M20.51
1.95%
61
Neutral
2.90B114.96
4.18%9.32%
146.11M54.93
65
Neutral
752.68M
17.69%14.51%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IL:NVLG
Novolog
140.40
-2.97
-2.07%
BRSYF
Brainsway
6.67
4.57
217.62%
IL:ILX
Ilex Medical
6,265.00
-75.87
-1.20%
IL:DANE
Danel
47,980.00
17,156.00
55.66%
IL:REKA
Rekah
1,249.00
-339.00
-21.35%
IL:SOFW
Sofwave
2,370.00
639.00
36.92%

Novolog Corporate Events

Novolog Updates Securities Registry Amid Strategic Option Exercises
Feb 17, 2025

Novolog has announced a change in its securities registry due to the exercise of employee options and the allocation of options to the Chairman of the Board. These changes include an increase in the number of securities and a private allocation to Altshuler Shaham Benefits Ltd., reflecting a strategic move to manage corporate shares and options effectively, potentially impacting shareholder value and market perception.

Novolog Announces Major Change in Securities Holdings
Feb 17, 2025

Novolog has reported a significant change in the holdings of securities, with Arie Schor, an interested party, increasing his holdings through a private placement. The change involved a single transaction resulting in an acquisition of 2,317,915 securities, now accounting for 100% of the current type of securities held. This adjustment reflects strategic positioning and could impact Novolog’s market dynamics by potentially influencing voting power and capital structure.

Novolog Announces Dividend Distribution for Shareholders
Feb 16, 2025

Novolog has announced a dividend distribution for its shareholders, with a record date of February 16, 2025. The company will distribute dividends at a rate of 0.44% to shareholders, which will be paid in cash, reflecting its adherence to its profit distribution policy.

Novolog Approves New Terms for Chairman’s Employment
Feb 13, 2025

Novolog held a special meeting to approve the terms of service and employment for the company’s Chairman of the Board, Mr. Arik Shor. The meeting, which required a regular majority for approval, concluded with the decision to approve the terms as outlined. This decision reflects an important operational update for Novolog, potentially affecting its governance structure and ensuring clarity in leadership roles.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025